Cellectis — Capital/Financing Update 2025

Jan 21, 2025

CORRESP 1 filename1.htm CORRESP

Cellectis S.A.

8, rue de la Croix Jarry

75013 Paris, France

January 21, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jason Drory

RE: Cellectis S.A.

Registration Statement on Form F-3 (File No. 333-284302)

Dear Mr. Drory:

In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Cellectis S.A. (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on January 23, 2025 at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant also hereby requests that the Commission notify Peter Devlin of Jones Day at 212-326-3978 or pdevlin@jonesday.com to confirm that the Registration Statement has become effective.

Please contact Peter Devlin of Jones Day if you have any questions concerning the foregoing. Thank you for your attention to this matter.

Very truly yours,
CELLECTIS S.A.
By:	/s/ André Choulika
	Name: André Choulika
	Title:  Chief Executive Officer

cc: Peter Devlin, Jones Day